: We’re What We are Treated with?Silvia Corcione 1,2, *, Ilaria De Benedetto 1 , Nour Shbaklo 1 , Giulia Torsello 3 , Tommaso Lupia four , Gabriele Bianco 5 , Rossana Cavallo 5 , Luca Brazzi 3 , Giorgia Montrucchio 3, and Francesco Giuseppe De Rosa 1,1 24*Department of Health-related Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy College of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA Division of Anesthesia, Intensive Care and Emergency–`Citt?della Salute e della Scienza’ Hospital, 10126 Turin, Italy Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy Microbiology and Virology Unit, University Hospital Citt?della Salute e della Scienza di Torino, 10126 Turin, Italy Correspondence: silvia.corcione@unito.it These authors contributed equally to this operate.Citation: Corcione, S.; De Benedetto, I.; Shbaklo, N.; Torsello, G.; Lupia, T.; Bianco, G.; Cavallo, R.; Brazzi, L.; Montrucchio, G.; De Rosa, F.G. Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We are What We are Treated with? Int. J. Mol. Sci. 2023, 24, 4767.2439223-60-4 Chemscene doi.org/10.3390/ ijms24054767 Academic Editor: Carlos Juan Nicolau Received: 31 December 2022 Revised: 20 February 2023 Accepted: 24 February 2023 Published: 1 MarchAbstract: The continuous spread of carbapenem-resistant Klebsiella pneumoniae (CP-Kp) strains presents a serious challenge towards the healthcare technique as a result of restricted therapeutic selections and higher mortality.(5-Methylthiophen-2-yl)methanol Order Considering the fact that its availability, ceftazidime/avibactam (C/A) has grow to be a first-line choice against KPC-Kp, but C/A-resistant strains happen to be reported increasingly, especially with pneumonia or prior suboptimal blood exposure to C/A remedy. A retrospective, observational study was carried out with all patients admitted for the Intensive Care Unit (ICU) devoted to COVID-19 individuals at the City of Well being Sciences in Turin, between 1 Might 2021 and 31 January 2022, using the major endpoint to study strains with resistance to C/A, and secondly to describe the qualities of this population, with or with out earlier exposure to C/A. Seventeen sufferers with colonization or invasive infection because of Klebsiella pneumoniae, C/A resistance, and susceptibility to meropenem (MIC = two /L) were included; the blaKPC genotype was detected in all isolates revealing D179Y mutation in the blaKPC-2 (blaKPC-33 ) gene. Cluster analysis showed that 16 out on the 17 C/A-resistant KPC-Kp isolates belonged to a single clone. Thirteen strains (76.5 ) had been isolated within a 60-day period. Only some individuals had a prior infection with non-mutant KPC at other sites (five; 29.four ). Eight sufferers (47.1 ) underwent preceding large-spectrum antibiotic treatment, and four sufferers (23.PMID:24065671 5 ) had prior therapy with C/A. The secondary spread on the D179Y mutation inside the blaKPC-2 during the COVID-19 pandemic must be addressed continuously by an interdisciplinary interaction in between microbiologists, infection handle personnel, clinicians, and infectious illnesses consultants to effectively diagnose and treat sufferers. Keywords and phrases: KPC; carbapenemases; ceftazidime/avibactam; resistance; D179Y1. IntroductionsCopyright: ?2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is definitely an open access write-up distributed beneath the terms and conditions with the Inventive Commons Attribution (CC BY) license ( creativecommons.org/licenses/by/ four.0/).The continuous spread of carbapenemase-producing Klebsi.
